US 11440963
Combination PDL1 and TGF-beta blockade in patients with HPV+ malignancies
granted A61KA61K2039/505A61K2039/507
Quick answer
US patent 11440963 (Combination PDL1 and TGF-beta blockade in patients with HPV+ malignancies) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Secretary, Department of Health and Human Services
- Grant date
- Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 22
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K39/3955, A61K45/06